Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-sm
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial - The Lancet Oncology
PDF) Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer
Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy - ScienceDirect
Visor Redalyc - Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation reporta
Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma | Future Oncology
Frontiers | Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial - The Lancet Oncology
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial - The Lancet Oncology
VARGATEF (nintedanib) - Safety Profile | Boehringer Ingelheim
studio LUME-Lung 1 Archivi • NCF - Notiziario Chimico Farmaceutico
Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation reporta
Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-sm
Difference between the absolute slD of target lesions (nintedanib... | Download Scientific Diagram
Articles Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer
Tumor growth over time: analysis of data from the LUME-Lung 1 trial
Lume-Lung 1: study design. NSCLC, non-small cell lung cancer. | Download Scientific Diagram
LUME-Lung 1
Nintedanib + docetaxel after immunotherapy in adenocarcinoma non-small cell lung cancer: first results from the non-intervention
Collective teaching of transverse flute as a component of a pulmonary rehabilitation program: An innovative study
Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line. - ppt download
Indication | Uses | VARGATEF® (nintedanib)
Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy - ScienceDirect
New Perspectives on Second-Line Therapy for NSCLC - ppt download
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer - ScienceDirect
